Global Whole Exome Sequencing Market to amass $3,812 Mn by 2027

December 10, 2019


According to the latest study titled ‘Whole Exome Sequencing Market to 2027 - Global Analysis and Forecasts By Products & Service (Systems, Kits, Services); Technology (Sequencing By Synthesis, Ion Semiconductor Sequencing, Other Technologies); Applications (Diagnostics, Drug Discovery & Development, Personalized Medicine, Others) and Geography’ available with Market Study Report LLC, the global whole exome sequencing market is estimated to accumulate US $3,812 million by the year 2027.
 

The growth of whole exome sequencing market is propelled by factors such as rising need of molecular diagnosis, reduction in time and cost for sequencing, and increasing application in drug discovery. Moreover, the next-generation sequencing has enabled effective analysis for phenotypic and genotypic relations among the human populations, aiding in the inference of genetics information for the drug development, thereby propelling market growth.
 

However, social, ethical and legal uncertainties regarding whole exome sequencing and lack of highly skilled professionals may hinder the growth of the industry. According to the study, the global whole exome sequencing market was valued at US $755.68 million in 2018 and is anticipated to grow with a CAGR of 19.8% over the analysis period.
 

The study encompasses details about market size based on revenue shares for each segment, alongside the expansion strategies adopted by manufacturers. It analyzes the market landscape using PEST analysis method and delivers expert opinions. Information about the market dynamics covering drivers and restraints is also outlined in the report.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2202059/
 

Based on products and services, whole exome sequencing market is segmented into kits, systems, and services. While as per technology, the industry is divided into ion semiconductor sequencing, sequencing by synthesis, and other technologies. Speaking of application spectrum, whole exome sequencing market is split into diagnostics, personalized medicine, drug discovery & development, and others.
 

Considering the geographical landscape, the global whole exome sequencing market is fragmented into regions which are North America, Europe, APAC, Middle East & Africa, and South & Central America.
 

Some of the vendors that operate in the global whole exome sequencing market are Centogene, Illumina, Inc., Thermo Fisher Scientific, Inc., Psomagen, Inc., GENEWIZ, Pacific Bioscience of California, Inc., F. Hoffmann-La Roche Ltd., Eurofins Scientific, Bio-Rad Laboratories, Inc., and Stratos Genomics.


Frequently Asked Questions (FAQ) :

The growth of whole exome sequencing market is propelled by factors such as rising need of molecular diagnosis, reduction in time and cost for sequencing, and increasing application in drug discovery. Moreover, the next-generation sequencing has enabled effective analysis for phenotypic and genotypic relations among the human populations, aiding in the inference of genetics information for the drug development, thereby propelling market growth.
The global whole exome sequencing market was valued at US $755.68 million in 2018 and is anticipated to grow with a CAGR of 19.8% over the analysis period, hence accumulating US $3,812 million by 2027.
Social, ethical and legal uncertainties regarding whole exome sequencing and lack of highly skilled professionals is presumed to hinder the growth of whole exome sequencing market in the upcoming years.
Companies that show prominence in the competitive landscape of whole exome sequencing market are Centogene, Illumina, Inc., Thermo Fisher Scientific, Inc., Psomagen, Inc., GENEWIZ, Pacific Bioscience of California, Inc., F. Hoffmann-La Roche Ltd, Eurofins Scientific, Bio-Rad Laboratories, Inc., and Stratos Genomics.